The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the society of gynecologic oncologists, a 5-year follow-up.
Citation: Gynecologic Oncology Reports. 20:47-50, 2017 MayPMID: 28317007Institution: MedStar Washington Hospital CenterDepartment: Obstetrics and GynecologyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: PubMed-not-MEDLINE -- Not indexedYear: 2017ISSN:- 2352-5789
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 28317007 | Available | 28317007 |
*NACT use among SGO members for ovarian cancer is explored given recent trials.*Fewer SGO members feel they can't predict optimal cytoreduction pre-operatively.*Laparoscopy use has increased both for diagnosis and treatment of ovarian cancer.*Very high optimal cytoreduction rates are reported from SGO members.*Despite recent studies, SGO members don't regularly treat patients with NACT/ID.
English